SCP
SymBiosis Capital Partners Portfolio holdings
AUM
$52.8M
This Fund
S&P 500
1 Year Est. Return
–
AUM
$52.8M
AUM Growth
-$56.7M
(-52%)
Holding
12
Top Sells
| 1 | +$15.4M | |
| 2 | +$13.2M | |
| 3 | +$12.5M | |
| 4 |
Nuvation Bio
NUVB
|
+$11.2M |
| 5 |
AARD
Aardvark Therapeutics
AARD
|
+$6.26M |
Sector Composition
| 1 | Healthcare | 95.97% |
| 2 | Consumer Staples | 4.03% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EVMN
1
Evommune Inc
EVMN
$855M
| $29.4M | 55.8% |
1,280,778
|
|
||
|
IVA
2
Inventiva
IVA
$1.12B
| $13.1M | 24.76% |
2,354,000
-246,000
|
|
||
3
Wave Life Sciences
WVE
$1.23B
| $5.44M | 10.3% |
+750,000
|
|
||
4
Rani Therapeutics
RANI
$91.5M
| $2.69M | 5.11% |
3,667,585
-2,632,415
|
|
||
5
Clene
CLNN
$83.4M
| $2.13M | 4.03% |
431,094
-339,401
|
|
||
6
Surrozen Inc Warrant
SRZNW
| $2.4K | ﹤0.01% |
150,000
|
|
||
7
AmpliTech
AMPG
$122M
| – | – |
-2,555,000
|
|
||
|
GBIO
8
DELISTED
Generation Bio
GBIO
| – | – |
-665,000
|
|
||
|
9
Nuvation Bio
NUVB
$1.66B
| – | – |
-1,250,000
|
|
||
10
Precigen
PGEN
$1.51B
| – | – |
-3,000,000
|
|
||
11
Verastem
VSTM
$391M
| – | – |
-2,000,000
|
|
||
|
AARD
12
Aardvark Therapeutics
AARD
$93.8M
| – | – |
-476,595
|
|